Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07290036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

StatusRecruiting
PhasePhase 1
Started2025-12-10
View on ClinicalTrials.gov ↗

Amendment history

2026-07-02
Study Status, Contacts/Locations v14
Study sites62→63
2026-06-18
Study Status, Contacts/Locations v13
Study sites61→62
2026-06-04
Study Status, Contacts/Locations v12
Trial sites expanded: 57 → 61 locations
2026-05-21
Study Status, Contacts/Locations v11
Trial sites expanded: 52 → 57 locations
2026-05-07
Study Status, Contacts/Locations v10
Trial sites expanded: 42 → 52 locations
2026-04-23
Study Status, Contacts/Locations v9
Trial sites expanded: 25 → 42 locations
2026-04-09
Study Status, Contacts/Locations v8
Trial sites expanded: 20 → 25 locations
Primary completion pushed: 2028-04-04 → 2028-05-18
Completion pushed: 2028-07-04 → 2028-09-14
2026-03-26
Study Status, Contacts/Locations v7
Study sites18→20
2026-03-12
Study Status, Contacts/Locations v6
Study sites17→18
2026-02-26
Study Status, Contacts/Locations v5
Study sites13→17
2026-02-17
Study Status, Contacts/Locations v4
Study sites10→13
2026-02-03
Study Status, Contacts/Locations v3
Study sites5→10
2026-01-05
Study Status, Conditions, Contacts/Locations v2
Study sites2→5
2025-12-18
Not Yet Recruiting→Recruiting Study Status, Conditions, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-12→confirmed 2025-12-10
Study sites0→2
2025-12-04
Original filing
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Trial Details
NCT Number NCT07290036
Lead Sponsor UCB Biopharma SRL
Conditions Psoriatic Arthritis, Axial Spondyloarthritis
Enrollment 392 participants
Start Date 2025-12-10
Primary Completion 2028-05-18 (estimated)
Study Completion 2028-09-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-06